Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Today at 2 PM, Akero Therapeutics Presented at the H.C. Wainwright 7th Annual NASH Virtual Investor Conference

October 24, 2023 0

Akero Therapeutics Presented at the H.C. Wainwright 7th Annual NASH Conference Indeed, today, Akero Therapeutics (AKRO) …

Intellia Therapeutics: FDA Clearance of its Systemically Administered NDA of NTLA-2001 in Global Phase 3 Trial

October 18, 2023 0

Intellia Therapeutics' NTLA-2001 Intellia Therapeutics' NTLA-2001 is the first-ever investigational in vivo CRISPR-based gene editing therapy …

Intellia Therapeutics Receives PRIME Designation from the EMA for NTLA-2002 – Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema

October 14, 2023 0

Intellia Therapeutics Receives PRIME Designation from EMA Intellia Therapeutics (NTLA) announced that the European Medicines Agency …

INOVIO Receives FDA Feedback that Data from Completed Phase 1/2 Trial of INO-3107 Can be Used to Submit a BLA

October 11, 2023 0

Inovio Receives FDA Feedback for INO-3107 INOVIO (INO) - a biotechnology company focused on developing and …

Akero Therapeutics’ October 10, 2023 Press Release

October 10, 2023 0

Akero Therapeutics Press Release Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, …

Please Don’t Miss Akero Therapeutics Investor Conference Tomorrow, October 10th at 8 AM

October 9, 2023 0

Akero Therapeutics to Present Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated …

Apellis Pharmaceuticals Announces Preliminary U.S. Net Revenues of Approximately $74 M for SYFOVRE® in the Q3 2023

October 6, 2023 0

Apellis Pharmaceuticals Launch Update of SYFOVRE® On October 5, 2023, Apellis Pharmaceuticals (APLS) provided an update …

Neurocrine Biosciences Announced Positive Results from Phase 3 CAHtalyst™ Study

October 5, 2023 0

Neurocrine Biosciences Announcement Today, Neurocrine Biosciences (NBIX) announced positive top-line data from the Phase 3 CAHtalyst™ …

Akero Therapeutics Announced Publication in the Lancet Gastroenterology & Hepatology of HARMONY Phase 2b Trial Results for NASH

October 4, 2023 0

Akero Therapeutics Akero Therapeutics (AKRO) announced publication in The Lancet Gastroenterology & Hepatology of results from …

Soleno Therapeutics Announces Positive Top-Line Results of Its Product DCCR for the Treatment of Prader-Willi Syndrome

September 28, 2023 0

Soleno Therapeutics Soleno Therapeutics (SLNO) is focused on the development and commercialization of novel therapeutics for …

Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast

September 26, 2023 0

Pliant Therapeutics in the NEWS Treating Primary Sclerosing Cholangitis Pliant Therapeutics (PLRX) today announced positive data …

Reata Stock Holders Approved the Firm’s Merger with Biogen

September 21, 2023 0

Reat Pharmaceuticals Merger with Biogen Reata Pharmaceuticals announced that at a special meeting held today, preliminary …

Publication of Two Cases for Treatment of Metastatic Pancreatic Cancer by CARsgen Therapeutics Holdings Limited

September 21, 2023 0

CARsgen Therapeutics Holdings Limited Today, September 21, 2023, CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK) - …

Orchard Therapeutics: FDA Acceptance of BLA Application for Product OTL-200 for the Treatment of Metachromatic Leukodystrophy

September 18, 2023 0

Orchard Therapeutics in the NEWS Today, September 18, 2023, Orchard Therapeutics (ORTX) - a global gene …

Discovering The Root Causes of Diseases

September 15, 2023 0

Prohost Letter #457 Discovering The Root Causes of Diseases Biotech firms with solid scientific fundamentals …

Neurocrine Biosciences: Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia

September 12, 2023 0

Neurocrine Biosciences in the NEWS Today, Neurocrine Biosciences (NBIX) announced positive top-line data from Phase 3 …

Crinetics Pharmaceuticals: Once Daily, Oral Investigational Product Met Primary and Secondary Endpoints in Phase 3 Treatment of Acromegaly

September 11, 2023 0

Crinetics Pharmaceuticals Once Daily, Oral Treatment for Acromegaly Crinetics Pharmaceuticals (CRNX) announced that its oral and …

Alpine Immune Sciences Treating IgA Nephropathy Among Other Diseases

August 31, 2023 0

Alpine Immune Sciences Treating IgA nephropathy Alpine Immune Sciences (ALPN) announced a successful initiation of the …

Halozyme Therapeutics ENHANZE Reduces Roche’s Tecentriq® Treatment Time to 7 Minutes from 30-60

August 29, 2023 0

Halozyme Therapeutics in the NEWS Halozyme Therapeutics (HALO) announced today that the Medicines and Healthcare Products …

Exelixis Positive Results in Phase 3 CABINET Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors

August 26, 2023 0

Exelixis in the NEWS Exelixis CABOMETYX is approved for the treatment of many cancers. The product …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

Today at 2 PM, Akero Therapeutics Presented at the H.C. Wainwright 7th Annual NASH Virtual Investor Conference

Intellia Therapeutics: FDA Clearance of its Systemically Administered NDA of NTLA-2001 in Global Phase 3 Trial

Intellia Therapeutics Receives PRIME Designation from the EMA for NTLA-2002 – Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema

INOVIO Receives FDA Feedback that Data from Completed Phase 1/2 Trial of INO-3107 Can be Used to Submit a BLA

Akero Therapeutics’ October 10, 2023 Press Release

Please Don’t Miss Akero Therapeutics Investor Conference Tomorrow, October 10th at 8 AM

Apellis Pharmaceuticals Announces Preliminary U.S. Net Revenues of Approximately $74 M for SYFOVRE® in the Q3 2023

Neurocrine Biosciences Announced Positive Results from Phase 3 CAHtalyst™ Study

Akero Therapeutics Announced Publication in the Lancet Gastroenterology & Hepatology of HARMONY Phase 2b Trial Results for NASH

Soleno Therapeutics Announces Positive Top-Line Results of Its Product DCCR for the Treatment of Prader-Willi Syndrome

Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast

Reata Stock Holders Approved the Firm’s Merger with Biogen

Publication of Two Cases for Treatment of Metastatic Pancreatic Cancer by CARsgen Therapeutics Holdings Limited

Orchard Therapeutics: FDA Acceptance of BLA Application for Product OTL-200 for the Treatment of Metachromatic Leukodystrophy

Discovering The Root Causes of Diseases

Neurocrine Biosciences: Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia

Crinetics Pharmaceuticals: Once Daily, Oral Investigational Product Met Primary and Secondary Endpoints in Phase 3 Treatment of Acromegaly

Alpine Immune Sciences Treating IgA Nephropathy Among Other Diseases

Halozyme Therapeutics ENHANZE Reduces Roche’s Tecentriq® Treatment Time to 7 Minutes from 30-60

Exelixis Positive Results in Phase 3 CABINET Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors